Related references
Note: Only part of the references are listed.A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
Brian A. Walker et al.
LEUKEMIA (2019)
Spectrum and functional validation of PSMB5 mutations in multiple myeloma
Santiago Barrio et al.
LEUKEMIA (2019)
Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients
John R. Jones et al.
HAEMATOLOGICA (2019)
Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
L. Rasche et al.
LEUKEMIA (2019)
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
Brian A. Walker et al.
BLOOD (2018)
The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma
Leo Rasche et al.
BLOOD (2018)
Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis
Marjorie Pick et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2018)
Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma
Faith E. Davies et al.
HAEMATOLOGICA (2018)
MRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored Treatment
Ola Landgren et al.
SEMINARS IN HEMATOLOGY (2018)
Maintaining therapeutic progress in multiple myeloma by integrating genetic and biological advances into the clinic
Gareth J. Morgan et al.
EXPERT REVIEW OF HEMATOLOGY (2018)
Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma
Faith E. Davies et al.
HAEMATOLOGICA (2018)
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
Aurore Perrot et al.
BLOOD (2018)
Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma
Molly Went et al.
NATURE COMMUNICATIONS (2018)
Subclonal TP53 copy number is associated with prognosis in multiple myeloma
Vallari Shah et al.
BLOOD (2018)
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
Wan-Hong Zhao et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
Yogesh S. Jethava et al.
CLINICAL CANCER RESEARCH (2017)
Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma
S. Mithraprabhu et al.
LEUKEMIA (2017)
Proteomic profiling in plasma cell disorders: a feasibility study
Sham Mailankody et al.
LEUKEMIA & LYMPHOMA (2017)
The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype
Carolina Schinke et al.
HAEMATOLOGICA (2017)
The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
Sharmilan Thanendrarajan et al.
HAEMATOLOGICA (2017)
Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study
Philippe Moreau et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
L. Rasche et al.
NATURE COMMUNICATIONS (2017)
Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates
Olena Kis et al.
NATURE COMMUNICATIONS (2017)
Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker
S. S. Chavan et al.
BLOOD CANCER JOURNAL (2017)
The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma
Caleb K. Stein et al.
ONCOTARGET (2017)
The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma
Yuji Mishima et al.
CELL REPORTS (2017)
The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype
Carolina Schinke et al.
HAEMATOLOGICA (2017)
The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
Sharmilan Thanendrarajan et al.
HAEMATOLOGICA (2017)
Evolutionary biology of high-risk multiple myeloma
Charlotte Pawlyn et al.
NATURE REVIEWS CANCER (2017)
Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma
Leo Rasche et al.
BLOOD (2017)
Immunologic approaches for the treatment of multiple myeloma
Leo Rasche et al.
CANCER TREATMENT REVIEWS (2017)
Clinical value of molecular subtyping multiple myeloma using gene expression profiling
N. Weinhold et al.
LEUKEMIA (2016)
Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and High-Risk Cytogenetic Features
Leo Rasche et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
Niels Weinhold et al.
BLOOD (2016)
Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes
K. Martin Kortum et al.
BLOOD (2016)
Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition
Marc S. Raab et al.
BLOOD (2016)
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Sagar Lonial et al.
LANCET (2016)
Genetic interrogation of circulating multiple myeloma cells at single-cell resolution
Jens G. Lohr et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients
K. M. Kortuem et al.
BLOOD CANCER JOURNAL (2016)
Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma
Y. Jethava et al.
BLOOD CANCER JOURNAL (2016)
Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M3P)
K. M. Kortuem et al.
ANNALS OF HEMATOLOGY (2015)
Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells
Tobias Meissner et al.
BMC MEDICAL GENOMICS (2015)
Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation
Mathew Weinstock et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma
Brian A. Walker et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma
L. Vincent et al.
BLOOD CANCER JOURNAL (2015)
Curing myeloma at last: defining criteria and providing the evidence
Bart Barlogie et al.
BLOOD (2014)
Vemurafenib Response in 2 Patients With Posttransplant Refractory BRAF V600E-Mutated Multiple Myeloma
J. P. Sharman et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2014)
Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma
L. Melchor et al.
LEUKEMIA (2014)
CANCER One cell at a time
Edward J. Fox et al.
NATURE (2014)
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
Niccolo Bolli et al.
NATURE COMMUNICATIONS (2014)
Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3
Saad Z. Usmani et al.
BLOOD (2013)
Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data
Sarah Waheed et al.
HAEMATOLOGICA (2013)
The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma
Niels Weinhold et al.
NATURE GENETICS (2013)
Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013
Joseph R. Mikhael et al.
MAYO CLINIC PROCEEDINGS (2013)
Targeting the BRAF V600E Mutation in Multiple Myeloma
Mindaugas Andrulis et al.
CANCER DISCOVERY (2013)
Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases
Leo Rasche et al.
ANNALS OF HEMATOLOGY (2012)
Darwinian evolution and tiding clones in multiple myeloma
Nizar J. Bahlis
BLOOD (2012)
Clonal competition with alternating dominance in multiple myeloma
Jonathan J. Keats et al.
BLOOD (2012)
Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents
Saad Z. Usmani et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
The genetic architecture of multiple myeloma
Gareth J. Morgan et al.
NATURE REVIEWS CANCER (2012)
Multiple Myeloma
Jacob Laubach et al.
ANNUAL REVIEW OF MEDICINE, VOL 62, 2011 (2011)
The prognostic significance of cytogenetics and molecular profiling in multiple myeloma
Jeffrey R. Sawyer
CANCER GENETICS (2011)
Renal function in newly diagnosed multiple myeloma - A demographic study of 1353 patients
Lene Meldgaard Knudsen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma
Twyla B. Bartel et al.
BLOOD (2009)
Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome
M. C. Minnema et al.
BONE MARROW TRANSPLANTATION (2008)
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
John D. Shaughnessy et al.
BLOOD (2007)
The molecular classification of multiple myeloma
Fenghuang Zhan et al.
BLOOD (2006)
Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients
JA Pérez-Simón et al.
LEUKEMIA (2006)
Molecular pathogenesis and a consequent classification of multiple myeloma
PL Bergsagel et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome
R Zeiser et al.
BONE MARROW TRANSPLANTATION (2004)
Share Paper
